Newbridge Financial Services Group’s Arcturus Therapeutics ARCT Stock Holding History

Newbridge Financial Services Group’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$269	Hold	40	–	–	﹤0.01%	1176
2026 Q1	$309	Buy	+40	New	+$292	﹤0.01%	1119
2023 Q1	–	Sell	-1,500	Closed	-$25.4K	–	1416
2022 Q4	$25.4K	Sell	1,500 -1,000	-40%	-$17.4K	0.01%	646
2022 Q3	$37K	Sell	2,500 -64	-2%	-$1.07K	0.02%	524
2022 Q2	$40K	Sell	2,564 -500	-16%	-$9.81K	0.02%	454
2022 Q1	$83K	Sell	3,064 -850	-22%	-$21.7K	0.04%	350
2021 Q4	$145K	Sell	3,914 -200	-5%	-$8.15K	0.07%	242
2021 Q3	$197K	Buy	4,114 +3,850	+1,458%	+$173K	0.12%	174
2021 Q2	$9K	Hold	264	–	–	0.01%	1001
2021 Q1	$11K	Sell	264 -329	-55%	-$19.6K	0.01%	860
2020 Q4	$26K	Buy	593 +500	+538%	+$33.9K	0.02%	472
2020 Q3	$4K	Buy	+93	New	+$4.62K	﹤0.01%	831

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Newbridge Financial Services Group's ARCT Position: Q2 2026 in Review

Newbridge Financial Services Group held its Arcturus Therapeutics (ARCT) position steady in Q2 2026 at 40 shares worth $269. The position accounts for ﹤0.01% of the portfolio, ranked #1176.

Newbridge Financial Services Group first reported a position in ARCT in Q3 2020 and has held it in 12 quarters since. The position peaked at $197K in Q3 2021. 136 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

Newbridge Financial Services Group held 40 shares of Arcturus Therapeutics worth $269 as of Q2 2026.
Newbridge Financial Services Group left its Arcturus Therapeutics share count unchanged in Q2 2026.
Arcturus Therapeutics made up ﹤0.01% of Newbridge Financial Services Group's portfolio in Q2 2026, its #1176 holding.
Newbridge Financial Services Group first reported a position in Arcturus Therapeutics in Q3 2020 and has held it in 12 quarters since.
Newbridge Financial Services Group's Arcturus Therapeutics position peaked at $197K in Q3 2021.
136 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Newbridge Financial Services Group's 13F filing for Q2 2026, filed 14 Aug 2026.